Trial Profile
A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary) ; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CanStem43L
- Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 19 Dec 2016 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.
- 19 Dec 2016 Status changed from not yet recruiting to recruiting.
- 14 Jul 2016 New trial record